PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
The developer of anti-inflammatory treatments will need to persuade investors to look past its balance sheet problems and its narrow pipeline of products Key Takeaways: The company is making a…
Recent Articles
RELATED ARTICLES
-
Struggling Shimao looks on as creditors move in on its trophy Hong Kong hotel
0813.HK - A healthy return: drug spin-off nets Keymed up to $320 million
- Mega licensing deal lifts 3SBio profits but core sales slip
- Asia’s probiotic leader looks for nourishment from Hong Kong IPO
- Extransfer seeks Hong Kong IPO as accounting losses hide a cash cow
- Cash-challenged Tenways cycles toward IPO
- Eye drug maker VivaVision feels the strain in IPO funding dash
